Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25975839 | 0.77 | MEN1 (0.33) | MEN1KMT2AKDM4EGAACYP2C9 | |
| SCHEMBL24659294 | 0.77 | MEN1 (0.33) | MEN1KMT2AKDM4EGAACYP2C9 | |
| SCHEMBL1692392 | 0.70 | — | — | |
| SCHEMBL1795212 | 0.69 | MEN1 (0.43) | MEN1KMT2AKDM4EGAACYP2C9 | |
| SCHEMBL14749867 | 0.69 | — | — | |
| SCHEMBL10176083 | 0.69 | — | — | |
| SCHEMBL5431792 | 0.67 | MEN1 (0.41) | MEN1KMT2AKDM4EGAACYP2C9 | |
| SCHEMBL16878106 | 0.67 | MEN1 (0.41) | MEN1KMT2AKDM4EGAACYP2C9 | |
| SCHEMBL17762890 | 0.67 | — | — | |
| SCHEMBL12056793 | 0.67 | EPHX1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250089-A1 | MAP4K3 SMALL MOLECULE DRUG INHIBITORS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250089-A1 | MAP4K3 SMALL MOLECULE DRUG INHIBITORS AND METHODS OF USE THEREOF | MAP4K3, MAP3K4, MAP3K3 | MEN1 2811/4885KMT2A 2752/4885KDM4E 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.